Differential toxicological response to positively and negatively charged nanoparticles in the rat brain

Nanotoxicology

Volumn 8, Issue 7, 2014, Pages 764-774

  Knudsen, Kristina Bram ^a,b   Northeved, Helle ^b   Ek, Pramod Kumar ^c   Permin, Anders ^c   Andresen, Thomas L ^c   Larsen, Steen ^b   Wegener, Karen Malene ^b   Lam, Henrik Rye ^c   Lykkesfeldt, Jens ^d  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b H LUNDBECK A S   (Denmark)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d DHI   (Denmark)

Author keywords

Apoptosis; Hippocampus; Liposomes; Micelles

Indexed keywords

LIPOSOME; NANOPARTICLE; CASPASE 3; MACROGOL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN TOXICITY; CLINICAL CHEMISTRY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HEMATOLOGY; HIPPOCAMPUS; HISTOLOGY; INJECTION SITE; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MICELLE; NERVE CELL; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; RAT; ZETA POTENTIAL; ANIMAL; BODY WEIGHT; BRAIN; BRAIN LEVEL; CHEMISTRY; CYTOLOGY; DRUG EFFECT; LIVER; ORGAN SIZE; PATHOLOGY; WISTAR RAT;

ANIMALS; APOPTOSIS; BODY WEIGHT; BRAIN; BRAIN CHEMISTRY; CASPASE 3; LIPOSOMES; LIVER; MALE; MICELLES; NANOPARTICLES; ORGAN SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, WISTAR;

EID: 84894586147     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2013.829589     Document Type: Article

References (63)

1. Altman J, Das GD. 1965. Autoradiographic and histological evidence of postnatal hippocampal neurogenesis in rats. J Comp Neurol 124 (3):319-335.
2. Andresen TL, Jensen SS, Jorgensen K. 2005. Advanced strategies in liposomal cancer therapy: problems and prospects of active and tumor specific drug release. Prog Lipid Res 44(1):68-97.
3. Andresen TL, Thompson DH, Kaasgaard T. 2010. Enzyme-triggered nanomedicine: drug release strategies in cancer therapy. Mol Membr Biol 27(7):353-363.
4. Arvizo RR, Miranda OR, Thompson MA, Pabelick CM, Bhattacharya R, Robertson JD, et al. 2010. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett 10(7):2543-2548.
5. Bessis A, Bechade C, Bernard D, Roumier A. 2007. Microglial control of neuronal death and synaptic properties. Glia 55(3):233-238.
6. Best PJ, White AM, Minai A. 2001. Spatial processing in the brain: the activity of hippocampal place cells. Annu Rev Neurosci 24:459-486.
7. Colvin VL, Kulinowski KM. 2007. Nanoparticles as catalysts for protein fibrillation. Proc Natl Acad Sci USA 104(21):8679-8680.
8. Daemen T, Hofstede G, Ten Kate MT, Bakker-Woudenberg IA, Scherphof GL. 1995. Liposomal doxorubicin-induced toxicity: depletion and impairment of phagocytic activity of liver macrophages. Int J Cancer 61(5):716-721.
9. Dai Z, Gjetting T, Mattebjerg MA, Wu C, Andresen TL. 2011. Elucidating the interplay between DNA-condensing and free polycations in gene transfection through a mechanistic study of linear and branched PEI. Biomaterials 32(33):8626-8634.
10. Dams ET, Oyen WJ, Boerman OC, Storm G, Laverman P, Kok PJ, et al. 2000. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J NuclMed 41(4):622-630.
11. Dokka S, Toledo D, Shi X, Castranova V, Rojanasakul Y. 2000. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes. Pharm Res 17(5):521-525.
12. Donaldson K. 2006. Resolving the nanoparticles paradox. Nanomedicine.( Lond) 1(2):229-234.
13. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA. 2003. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199(2):221-228.
14. Gao H, Shi W, Freund LB. 2005. Mechanics of receptor-mediated endocytosis. Proc Natl Acad Sci USA 102(27):9469-9474.
15. Gjetting T, Andresen TL, Christensen CL, Cramer F, Poulsen TT, Poulsen HS. 2011. A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that mediate high accumulation and reporter gene activity in tumor tissue. Results Pharm Sci 1(1):49-56.
16. Hu YL, Gao JQ. 2010. Potential neurotoxicity of nanoparticles. Int J Pharm 394(1-2):115-121.
17. Kagan VE, Bayir H, Shvedova AA. 2005. Nanomedicine and nanotoxicology: two sides of the same coin. Nanomedicine 1(4):313-316.
18. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. 1995. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res 674(1):171-174.
19. Kreuter J, Gelperina S. 2008. Use of nanoparticles for cerebral cancer. Tumori 94(2):271-277.
20. Kreuter J. 2001. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47(1):65-81.
21. Kuhn HG, Dickinson-Anson H, Gage FH. 1996. Neurogenesis in the dentate gyrus of the adult rat: age-related decrease of neuronal progenitor proliferation. J Neurosci 16(6):2027-2033.
22. Li N, Sioutas C, Cho A, Schmitz D, Misra C, Sempf J, et al. 2003. Ultrafine particulate pollutants induce oxidative stress and mitochondrial damage. Environ Health Perspect 111(4):455-460.
23. Linkov I, Satterstrom FK, Corey LM. 2008. Nanotoxicology and nanomedicine: making hard decisions. Nanomedicine 4(2):167-171.
24. Linse S, Cabaleiro-Lago C, Xue WF, Lynch I, Lindman S, Thulin E, et al. 2007. Nucleation of protein fibrillation by nanoparticles. Proc Natl Acad Sci USA 104(21):8691-8696.
25. Lo EH, Singhal AB, Torchilin VP, Abbott NJ. 2001. Drug delivery to damaged brain. Brain Res Brain Res Rev 38(1-2):140-148.
26. Lv H, Zhang S, Wang B, Cui S, Yan J. 2006. Toxicity of cationic lipids and cationic polymers in gene delivery. J Control Release 114 (1):100-109.
27. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. 2007. Nanoparticles: pharmacological and toxicological significance. Br J Pharmacol 150(5):552-558.
28. Mignone JL, Kukekov V, Chiang AS, Steindler D, Enikolopov G. 2004. Neural stem and progenitor cells in nestin-GFP transgenic mice. J Comp Neurol 469(3):311-324.
29. Minchin R. 2008. Nanomedicine: sizing up targets with nanoparticles. Nat Nanotechnol 3(1):12-13.
30. Moghimi SM, Hamad I. 2008. Liposome-mediated triggering of complement cascade. J Liposome Res 18(3):195-209.
31. Moghimi SM, Hunter AC. 2001. Recognition by macrophages and liver cells of opsonized phospholipid vesicles and phospholipid headgroups. Pharm Res 18(1):1-8.
32. Moghimi SM, Kissel T. 2006. Particulate nanomedicines. Adv Drug Deliv Rev 58(14):1451-1455.
33. Mullen RJ, Buck CR, Smith AM. 1992. NeuN, a neuronal specific nuclear protein in vertebrates. Development 116(1):201-211.
34. Myer DJ, Gurkoff GG, Lee SM, Hovda DA, Sofroniew MV. 2006. Essential protective roles of reactive astrocytes in traumatic brain injury. Brain 129(Pt 10):2761-2772.
35. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, et al. 1997. Positively charged liposome functions as an efficient immunoadjuvant in inducing immune responses to soluble proteins. Biochem Biophys Res Commun 240(3):793-797.
36. Nakanishi T, Kunisawa J, Hayashi A, Tsutsumi Y, Kubo K, Nakagawa S, et al. 1999. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release 61(1-2):233-240.
37. Nel A, Xia T, Madler L, Li N. 2006. Toxic potential of materials at the nanolevel. Science 311(5761):622-627.
38. Nel AE, Madler L, Velegol D, Xia T, Hoek EM, Somasundaran P, et al. 2009. Understanding biophysicochemical interactions at the nanobio interface. Nat Mater 8(7):543-557.
39. Oberdorster G, Oberdorster E, Oberdorster J. 2005. Nanotoxicology: an emerging discipline evolving from studies of ultrafine particles. Environ Health Perspect 113(7):823-839.
40. Oberdorster G, Stone V, Donaldson K. 2007. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1:12-25.
41. O?Callaghan JP, Jensen KF. 1992. Enhanced expression of glial fibrillary acidic protein and the cupric silver degeneration reaction can be used as sensitive and early indicators of neurotoxicity. Neurotoxicology 13(1):113-122.
42. O?Callaghan JP. 1991. Assessment of neurotoxicity: use of glial fibrillary acidic protein as a biomarker. Biomed Environ Sci 4(1-2):197-206.
43. O?Callaghan JP. 1994. Biochemical analysis of glial fibrillary acidic protein as a quantitative approach to neurotoxicity assessment: advantages, disadvantages and application to the assessment of NMDA receptor antagonist-induced neurotoxicity. Psychopharmacol Bull 30(4):549-554.
44. Ohsawa K, Imai Y, Sasaki Y, Kohsaka S. 2004. Microglia/macrophagespecific protein Iba1 binds to fimbrin and enhances its actin-bundling activity. J Neurochem 88(4):844-856.
45. Owens DE 3rd, Peppas NA. 2006. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307 (1):93-102.
46. Park JH, Lee S, Kim JH, Park K, Kim K, Kwon IC. 2008. Polymeric nanomedicine for cancer therapy. Prog Polym Sci 33(1):113-137.
47. Paxinos G, Watson C. 2008. The rat brain in stereotaxic coordinates. 6th ed. pp 1-400.
48. Peers PV, Cusack R, Duncan J. 2006. Modulation of spatial bias in the dual task paradigm: evidence from patients with unilateral parietal lesions and controls. Neuropsychologia 44(8):1325-1335.
49. Rochefort C, Arabo A, Andre M, Poucet B, Save E, Rondi-Reig L. 2011. Cerebellum shapes hippocampal spatial code. Science 334 (6054):385-389.
50. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, et al. 2005. Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer?s disease. J Control Release 108(2-3):193-214.
51. Sapra P, Allen TM. 2003. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 42(5):439-462.
52. Scheule RK, St George JA, Bagley RG, Marshall J, Kaplan JM, Akita GY, et al. 1997. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther 8(6):689-707.
53. Schmued LC, Hopkins KJ. 2000a. Fluoro-Jade B: a high affinity fluorescent marker for the localization of neuronal degeneration. Brain Res 874(2):123-130.
54. Schmued LC, Hopkins KJ. 2000b. Fluoro-Jade: novel fluorochromes for detecting toxicant-induced neuronal degeneration. Toxicol Pathol 28(1):91-99.
55. Sharma HS, Sharma A. 2007. Nanoparticles aggravate heat stress induced cognitive deficits, blood-brain barrier disruption, edema formation and brain pathology. Prog Brain Res 162:245-273.
56. Shvedova AA, Kisin ER, Porter D, Schulte P, Kagan VE, Fadeel B, et al. 2009. Mechanisms of pulmonary toxicity and medical applications of carbon nanotubes: Two faces of Janus? Pharmacol Ther 121 (2):192-204.
57. Soenen SJ, Brisson AR, De Cuyper M. 2009. Addressing the problem of cationic lipid-mediated toxicity: the magnetoliposome model. Biomaterials 30(22):3691-3701.
58. Szebeni J, Bedocs P, Rozsnyay Z, Weiszh?r Z, Urbanics R, Rosivall L, et al. 2011. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of doxil and ambisome. Nanomedicine 8(2):176-184.
59. Szebeni J, Moghimi SM. 2009. Liposome triggering of innate immune responses: a perspective on benefits and adverse reactions. J Liposome Res 19(2):85-90.
60. Szebeni J. 2005. Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity. Toxicology 216 (2-3):106-121.
61. Thomas M, Klibanov AM. 2003. Non-viral gene therapy: polycation- mediated DNA delivery. Appl Microbiol Biotechnol 62 (1):27-34.
62. Vega-Villa KR, Takemoto JK, Yanez JA, Remsberg CM, Forrest ML, Davies NM. 2008. Clinical toxicities of nanocarrier systems. Adv Drug Deliv Rev 60(8):929-938.
63. Zhang YF, Boado RJ, Pardridge WM. 2003. Absence of toxicity of chronic weekly intravenous gene therapy with pegylated immunoliposomes. Pharm Res 20(11):1779-1785.